Sarasota Memorial -- recognized repeatedly as one of America's Best Hospitals by U.S. News & World Report, and one of America's Safest Large Hospitals by Forbes -- is one of only 4.1 percent of U.S. hospitals at Stage 4 of the HIMSS Analytics EMR Adoption Model(SM), which is designed to assess the penetration of clinical information technology use within U.S. healthcare organizations. Overall nearly half (49 percent) of American hospitals have yet to reach Stage 3 on the EMR Adoption Model. The 806-bed community hospital on Florida's Gulf Coast has been using Eclipsys' health information technology to redesign its workflow processes and improve care quality and efficiency since 1998. Since that time, the hospital has developed a fully integrated system, redesigning its workflow systems and replacing virtually all of its paper documentation with electronic processes.

Physicians, nurses and other care providers now place 99.9 percent of the hospital's patient care orders and care notes electronically, reducing the risks associated with illegible handwritten orders and providing physicians with rapid access to their patient's medical history, test results and other information needed for clinical decision-making. The electronic medical record (EMR) also offers allergy and medication safety alerts and lets physicians instantly review and manage their patients' care at any time from any place they have internet access -- from their homes, their offices, even their cars.

The results have been well received: Improved turnaround times for X-rays, lab work and other tests, as well as fewer delays between order submission and administration of medications. Physicians and nurses no longer waste time searching the chart for paper lab slips or reports or clarifying illegible orders, and in many cases, electronic order sets have standardized "best practices" for nurses and doctors.

"We have the highest regard for Sarasota's leadership in their use of HIT to improve the quality, safety and efficiency of patient care," said Jay Deady, Eclipsys' executive vice president of Client Solutions. "Given the low level of technology adoption among U.S. hospitals today, this order entry milestone demonstrates the distinguished leadership within the Eclipsys client base. It also showcases our clients' satisfaction with superior solutions that offer highly complex clinical decision support capabilities and workflows that can be easily tailored to how physicians practice medicine."

Nationwide, scores of Eclipsys client hospitals and health systems are achieving high CPOE adoption and outcomes. A few examples include:

-- St. Clair Hospital (Pittsburgh, PA) has successfully used Eclipsys' CPOE solution to standardize anticoagulant therapies to prevent patient blood clotting. St. Clair's CPOE heparin infusion protocols, for example, have resulted in a 43 percent reduction in heparin infusion-related occurrences in inpatient units and an overall hospital reduction of 24 percent.

-- Bronx Lebanon Hospital Center (Bronx, NY), the largest voluntary, not-for-profit healthcare system in south and central Bronx, recently activated Eclipsys' ambulatory EHR, Sunrise Ambulatory Care(TM) in a 40-doctor multispecialty clinic in less than six months. The activation builds upon the successful use of Eclipsys' CPOE solution at its 579-bed hospital. Because of the integration between the two solutions, most of the orders set templates required for the ambulatory EHR were already in place.

-- Children's Hospital & Medical Center (Omaha, NE) has achieved a voluntary adoption rate of CPOE of 79 percent. Prescribing and transcription mediation errors reaching the patient fell from 0.89/1000 orders to 0.51/1000 orders for orders entered via CPOE. Transcription errors were eliminated when CPOE was used.

Eclipsys' CPO solution, Sunrise Acute Care(TM), contains the input of thousands of physicians for evidence-based order sets and frequently used protocols to achieve unmatched, continuous evolution in its clinical decision support and order entry application. The intuitive, easy-to-adopt solution supports fully automating even the most complex order sets and medication ordering, including the exacting protocols, long-range medication schedules and complicated treatment plans commonplace in oncology and pediatric care environments.

According to the KLAS CPOE Digest 2009: Meaningful Use and Physician Adoption report, 25 percent of the total number of doctors doing CPOE on a commercial system use Eclipsys. The company also continues to have the highest physician satisfaction from clients who use its system, and on average, highly customizable ordering capabilities allow a physician to order faster than any other CPOE solution on the market.

About Sarasota Memorial Health Care System

Founded in 1925, Sarasota Memorial Health Care System is the second-largest acute care public health system in Florida, with about 4,000 staff, 750 physicians and about 500,000 ER, inpatient and outpatient visits a year. With an 806-bed acute care hospital and comprehensive network of outpatient services -- pain care, rehabilitation, diagnostic imaging and laboratory, home health and a nursing home among its many services -- Sarasota Memorial offers the region's greatest breadth and depth of care. It is the only hospital in Southwest Florida that has ranked repeatedly among U.S. News & World Report's "America's Best Hospitals," the only one recognized among "America's Safest Large Hospitals" by Forbes and the only one awarded Magnet Nursing Services Recognition -- the nation's highest honor for excellence in nursing. For more information see www.smh.com.

About the HIMSS Analytics EMR Adoption Model(SM)

HIMSS Analytics, the authoritative source on EMR Adoption trends, devised the EMR Adoption Model to track EMR progress at hospitals and health systems. The EMRAM scores hospitals in the HIMSS Analytics Database on their progress in completing the 8 stages to creating a fully paperless patient record environment. For more information see www.himssanalytics.org.

About the KLAS CPOE Digest 2009

The KLAS CPOE Digest 2009 compiled data from healthcare executives, managers and clinicians. The study provided detailed information on several criteria including current CPOE usage at healthcare organizations, product capabilities and vendor performance.

About KLAS

KLAS is a research firm specializing in monitoring and reporting the performance of healthcare vendors. KLAS' mission is to improve delivery, by independently measuring vendor performance for the benefit of its healthcare provider partners, consultants, investors, and vendors. Working together with executives from over 4500 hospitals and over 2500 clinics, KLAS delivers timely reports, trends, and statistics, which provide a solid overview of vendor performance in the industry. KLAS measures performance of software, professional services, and medical equipment vendors. For more information, go to www.KLASresearch.com , email marketing@KLASresearch.com , or call 1-800-920-4109 to speak with a KLAS representative.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services that help healthcare organizations improve clinical, financial and operational outcomes. For more information, see www.eclipsys.com or email info@eclipsys.com.

Statements in this news release concerning the timing of implementation and features and benefits provided by Eclipsys software, ARRA qualification, evidence-based content and implementation services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client's circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from Eclipsys software or services. The success and timeliness of the company's services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and the contract can be terminated or its scope reduced under certain circumstances. ARRA qualification requires compliance with standards that are still evolving, and satisfaction of those standards may be delayed. More information about company risks is available in recent Form 10-Q and 10-K filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Eclipsys Corporation and The Outcomes Company are registered trademarks of Eclipsys Corporation. Sunrise Ambulatory Care and Sunrise Acute Care are trademarks of Eclipsys Corporation. Other product and company names in this news release are or may be trademarks and/or registered trademarks of their respective companies.

SOURCE: Eclipsys Corporation

Eclipsys Corporation 
Robin Wrinn, 404-847-5219 
Director, Public Relations (media) 
robin.wrinn@eclipsys.com 
or 
Jason Cigarran, 404-847-5965 
Vice President, Investor Relations 
jason.cigarran@eclipsys.com 
or 
Sarasota Memorial Health Care System: 
Kim Savage, 941-917-6271 
Media Relations 
kim-savage@smh.com

The "big bang" activation of Sunrise Patient Flow was completed in approximately five months -- and without any major disruption in SGH's care delivery. Remarkably, hospital leaders continued with the implementation while the hospital simultaneously dealt with the emergence of the H1N1 pandemic. The experience gave the team insights on how to enhance the system further to support future pandemic situations.

Upon entering the hospital, each SGH inpatient receives a radio frequency identification (RFID) tag. A real-time location system (RTLS) identifies patient location via the tag-- and automates workflow related to patient movements. As a result, the system enables SGH staff -- whether clinical, administrative or support -- to eliminate manual tasks related to the movement of patients through the system. Instead of requiring staff members to make multiple phone calls to one another in an attempt to coordinate patient flow, the system automates communicating "current" activities and "next step" requests. These tightly coupled and integrated systems are designed to reduce the amount of time that clinical and support staff spends behind the computer, enabling them to allot more time to focus on patient care.

The deployment of Eclipsys' enterprise-wide patient flow system included its Bed Turnover module, which is providing SGH's Environmental Services with the tools necessary to automate and manage bed cleaning requests, as well as housekeeping staff assignments to facilitate the timely cleaning and turnover of beds for incoming patients. The Bed Turnover module enables real-time communication via mobile personal digital assistants (PDAs) to notify housekeeping staff of assignments and coordinate progress, further optimizing and streamlining workflow and bed turnover time.

In addition, advanced interfaces enable Sunrise Patient Flow to share information with a variety of ancillary and administrative systems. For example, it integrates with the emergency department system to coordinate bed requests and placement decisions. It also "communicates" with SGH's third-party patient administration and billing system. Visual alerts and graphic screens presented via a real-time dashboard drive caregiver priorities, prompting the most efficient delivery of care.

"The SGH activation is certainly an important milestone for this valued client and for our company," said Tim Rutledge, Eclipsys' senior vice president of Enterprise Performance Management. "Our structured project methodology and strong partnership approach has enabled us to help our clients activate quickly and see a fast ROI. The fact that we were successful in activating an international client of this size, scale and complexity validates our process and confirms the strengths of our solution."

Sunrise Patient Flow provides both automated workflow and communications combined with real-time clinical visibility provides greater patient safety, improved clinical workflow and enhanced clinician/staff utilization. The Sunrise Patient Flow platform is built with Microsoft technologies and leverages the latest .NET, WPF, and SQL Server technologies to facilitate rapid and flexible client deployments as well as significant usability advantages. Sunrise Patient Flow, together with the Sunrise EPSi(TM) decision support and analytic solutions and Eclipsys' clinical analytics solution, comprise the Eclipsys' Enterprise Performance Management(TM) solution suite.

About Singapore General Hospital

Singapore General Hospital (SGH), a member of Singapore Health Services, is the public sector's flagship hospital. Established in 1821, SGH is Singapore's largest acute tertiary hospital and national referral centre offering a comprehensive range of clinical specialties and clinical support services in the region with 1,500 acute beds and about 500 specialists. Annually, 70,000 patients are admitted to the hospital and 600,000 patients attend outpatient clinics. For more information, see www.sgh.com.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services that help healthcare organizations improve clinical, financial and operational outcomes. For more information, see www.eclipsys.com or email info@eclipsys.com.

Statements in this news release concerning the timing of implementation and features and benefits provided by Eclipsys software, evidence-based content and implementation services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client's circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from Eclipsys software or services. The success and timeliness of the company's services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and the contract can be terminated or its scope reduced under certain circumstances. More information about company risks is available in recent Form 10-Q and 10-K filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Eclipsys Corporation and The Outcomes Company are registered trademarks of Eclipsys Corporation. Sunrise Patient Flow, Sunrise EPSi and Enterprise Performance Management are trademarks of Eclipsys Corporation. Other product and company names in this news release are or may be trademarks and/or registered trademarks of their respective companies.

SOURCE: Eclipsys Corporation

Eclipsys Corporation 
Robin Wrinn, 404-847-5219 
Director, Public Relations (media) 
robin.wrinn@eclipsys.com 
or 
Jason Cigarran, 404-847-5965 
Vice President, Investor Relations 
jason.cigarran@eclipsys.com 
or 
Singapore General Hospital: 
Junaidah Hameed, (65) 6321-3553 
Communications (Media) 
junaidah.hameed@sgh.com.sg

In a press release out on November 16, Nabi Biopharmaceuticals to Hold Conference Call

ROCKVILLE, Md., Nov 16, 2009 -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that it will host a live webcast and conference call at 11:00 a.m. ET on Tuesday, November 17 to discuss today's announcement of the exclusive worldwide option and licensing agreement for NicVAX(R), a nicotine conjugate candidate vaccine, between GlaxoSmithKline Biologicals SA and Nabi Biopharmaceuticals.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(R) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.com

Avago Technologies (Nasdaq:AVGO) trading at $15.65 per share on trading volume of 535 shares.

In a press release out on November 16, Avago Technologies Ramps Up Production of Its QSFP+ Active Optical Cable and Transceiver Solutions

Company's QSFP+ 4x10Gbps Infiniband Solutions Expands Reach While Lowering Power and Improving EMI Over Copper Interconnect Solutions

PORTLAND, Ore., Nov 16, 2009 -- Avago Technologies (Nasdaq:AVGO), a leading supplier of analog interface components for communications, industrial and consumer applications, will showcase its leading QSFP+ active optical cable (AOC) and transceiver solutions for short range Infiniband and Ethernet applications this week at Supercomputing 09. Avago's AFBR-79Q4xACyyZ is a high performance integrated cable for short-range multi-lane data communication and interconnect applications. It integrates four data lanes in each direction with 40Gbps aggregate bandwidth into a single module. Each lane can operate at 10 Gbps with lengths ranging from 1 to 100 meters.

About Avago Technologies

Avago Technologies is a leading supplier of analog interface components for communications, industrial and consumer applications. By leveraging its core competencies in III-V compound and silicon semiconductor design and processing, the company provides an extensive range of analog, mixed signal and optoelectronics components and subsystems to approximately 40,000 end customers. Backed by strong customer service support, the company's products serve four diverse end markets: wireless communications, wired infrastructure, industrial and automotive electronics, and consumer and computing peripherals. Avago has a global employee presence and heritage of technical innovation dating back 40 years to its Hewlett-Packard roots. Information about Avago is available on the Web at www.avagotech.com

Eclipsys Corporation(R) (NASDAQ: ECLP) trading at $19.93 on a volume of 60,162 shares

In a press release out on November 16, Singapore General Hospital Activates Eclipsys' Sunrise Patient Flow

One of World's Largest Bed Management and Radio Frequency Identification Deployments for Patient Location Tracking Occurs On Time and On Budget

ATLANTA, Nov 16, 2009 -- Eclipsys Corporation(R) (NASDAQ: ECLP), The Outcomes Company(R), today announced that Singapore General Hospital (SGH), Singapore's oldest and largest acute tertiary hospital and national referral center, has successfully activated Eclipsys' Sunrise Patient Flow(TM) solution. The on-time, on-budget technology, automation and process redesign project illustrates how Eclipsys' integrated and intuitive bed management, bed turnover and patient flow system can quickly bring operational improvements to even the most complex healthcare organizations. With 1,500-beds in its acute care environment, and treating 70,000 patients annually, SGH is successfully using Sunrise Patient Flow to improve the workflows and communications of its clinical, administrative and support staff. Combined with real-time clinical visibility, the solution is yielding substantial clinical and operational advantages as it supports the goal of optimized patient throughput and efficient delivery of patient care.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services that help healthcare organizations improve clinical, financial and operational outcomes. For more information, seewww.eclipsys.com or email info@eclipsys.com.

Mellanox(R) Technologies, Ltd. (NASDAQ:MLNX) (TASE:MLNX) trading at $18.70 on a volume of 52,171 shares

In a press release out on November 16, Mellanox Introduces CORE-Direct, Industry's Most Advanced Application Offloading Technology for High-Performance Computing Systems

ConnectX(R)-2 InfiniBand Adapters with CORE-Direct(TM) (Collectives Offload Resource Engine) Capabilities Provide Next Evolutionary Step for HPC Cluster Efficiency

PORTLAND, Ore., Nov 16, 2009 -- Mellanox(R) Technologies, Ltd. (NASDAQ:MLNX) (TASE:MLNX), a leading supplier of end-to-end connectivity solutions for data center servers and storage systems, today announced the availability of ConnectX-2 adapter products with CORE-Direct, application acceleration and scaling technology. The new capabilities in ConnectX-2 mark the next evolutionary step in High-Performance Computing (HPC) interconnect solutions that will enable significant improvements in application performance and scalability, and thus increase the productivity of compute centers.

About Mellanox

Mellanox Technologies is a leading supplier of end-to-end connectivity solutions for servers and storage that optimize data center performance. Mellanox products deliver market-leading bandwidth, performance, scalability, power conservation and cost-effectiveness while converging multiple legacy network technologies into one future-proof solution. For the best in performance and scalability, Mellanox is the choice for Fortune 500 data centers and the world's most powerful supercomputers. Founded in 1999, Mellanox Technologies is headquartered in Sunnyvale, California and Yokneam, Israel. For more information, visit Mellanox at www.mellanox.com.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

"We are committed to providing our patients with consistent high-quality care and taking full advantage of technologies that share evidence-based guidelines and support reducing variability in care," said John Heer, chief executive officer of North Mississippi Health Services, which includes NMMC and NMMC Women's Hospital in Tupelo, as well as community hospitals in Eupora, Iuka, Pontotoc and West Point, MS, and Hamilton, AL. "By undertaking this broader technology initiative, including adoption of Eclipsys' computerized physician order entry solution, we're equipping physicians with in-depth research clinical content at the point of care, as well as easy, secure access to the latest patient information from their offices, homes or other locations."

Plans call for NMMC to upgrade its Eclipsys technology infrastructure in a rolling facility "big bang" approach, beginning with the major referral center, NMMC - Tupelo, followed by NMMC's six affiliated community hospitals.

"We've already established a single, integrated health record spanning all venues of care based on our 26-year relationship with Eclipsys," said T.E. Bozeman, chief information officer of North Mississippi Health Services. "To meet the higher threshold ARRA requirements, we're electing to continue our Eclipsys partnership because the litmus test for this legislation is to utilize technology in such a way that it maximizes the value to physicians and ultimately patients. Eclipsys has a demonstrated track record of on-time on-budget implementations, plus exemplary success in helping organizations achieve physician adoption of and meaningful outcomes from technology. We look forward to working with Eclipsys to further enhance and automate our care processes and qualify for federal stimulus dollars."

Eclipsys is a provider of integrated clinical, revenue cycle and performance management software, clinical content and professional services.

((Comments on this story may be sent to health@closeupmedia.com))